Janus Henderson Capital Funds Plc - Global Life Sciences Fund on argenx SE
Thesis
Argenx was a leading contributor during August following positive phase 3 results for Vyvgart in autoimmune myositis. The treatment significantly improved muscle strength and physical function compared with placebo. The benefits were rapid and sustained and the trial achieved a statistically significant outcome, reinforcing the clinical case for the product.
“Vyvgart significantly improved muscle strength and physical function in adults with autoimmune myositis.”